In 2006 Stehlin Foundation became part of CHRISTUS Health, an international faith-based nonprofit healthcare system comprised of more than 50 hospitals and long-term care facilities, 175 clinics and outpatient centers, and dozens of other health ministries. CHRISTUS Health expresses its core values as:
The Sisters of Charity of the Incarnate Word are a multicultural, international Congregation of Catholic religious women based in Houston, Texas. The Congregation was founded in 1866 to minister to the sick, the poor and the deprived, with a sense of church that embraces all God’s people.
The Congregation spreads its healing ministry to those in need through direct patient contact and sponsorships, including two of the largest Catholic health care systems in the nation, Catholic Healthcare West and CHRISTUS Health.
The Sisters of Charity have been active, loyal, and generous supporters of the Foundation for more than 40 years.
The relationship began with a deep connection based on empathy for patients, shared by Dr. John S. Stehlin and Sister Mary David Gorman, the Congregation leader in 1967. Together these two visionaries created many “firsts” in humanistic cancer treatment at St. Joseph’s Hospital in Houston.
The Sisters were also instrumental in forging the relationship between the Foundation and CHRISTUS Health, ensuring our future as a research organization.
The Sisters’ spiritual guidance has helped the Foundation remain centered on people – on patients and their families – and most importantly, on FAITH and HOPE.
April 22, 2012
Combining a spirit of fun with a worthy philanthropic effort, Susan's Rally takes participants on an afternoon adventure in their automobiles and raises money for the fight against breast cancer!
“The new facility for the CHRISTUS Stehlin Foundation is an appropriate setting for an organization that has made an enormous contribution to the ongoing battle against cancer.”
Sister Lillian Anne Healy, CCVI,
Congregational Leader for Sister of Charity of the Incarnate Word
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.
Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer.